Informa
TIDES Europe: Oligonucleotide and Peptide Therapeutics
2024年11月12-14日
ドイツ、ハンブルク、CCH - Congress Center Hamburg

Main Conference Day 2 - CET (Central European Time, GMT+01:00)

Main Conference Day 2 - CET (Central European Time, GMT+01:00)

search
07:30 - 08:0030 mins
Morning Spotlight Presentation
Electrostatic Drying Technology and Solvent-Based Therapeutics - Solvent Removal and Drying in a One-Step Process
  • Jyothi Rangineni, PhD - Senior Process Scientist, Fluid Air
08:00 - 08:055 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairpersons Remarks: Oligonucleotide Preclinical and Clinical Updates
  • Yogesh Sanghvi, PhD - President, Rasayan Inc.
08:00 - 08:055 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Chairwoman's Remarks: Case Studies of Innovations and Efficiencies in Oligonucleotide CMC
  • Sonja Merkas, Ph.D. - Founder, Livinovea
08:00 - 08:055 mins
Peptide Discovery to CMC
Chairman’s Remarks: Trends in Peptide Discovery and Synthesis
  • Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
08:05 - 08:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
New Weapons Against Multidrug Resistant Bacterial Infections via an RNA Therapeutics Antibiotic Drug Discovery Platform
  • Peter Nielsen, PhD - Professor, University of Copenhagen
08:05 - 08:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Scaling Up Solution Phase Oligo Manufacturing and Future Innovations
  • Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
08:05 - 08:3530 mins
Peptide Discovery to CMC
Discovery and Development of Disulfide-constrained Peptides
  • Christina Schroeder, Ph.D. - Senior Fellow, Peptide Therapeutics, Genentech
08:35 - 09:0530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Using the L-stereoisomer RNA Aptamer NOX-A12 to Enhance Efficacy in Solid Tumors
  • Aram Mangasarian, Ph.D. - Chief Executive Officer, TME Pharma
08:35 - 09:0530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
.Biocatalytic Approaches to Oligonucleotides Manufacturing, a CMC Perspective
  • Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
08:35 - 09:0530 mins
Peptide Discovery to CMC
Development of Membrane-Permeable Cyclic Peptides
  • Christian Heinis, PhD - Associate Professor, Ecole PolyTechnique Federale de Lausanne
09:05 - 09:3530 mins
Oligonucleotide Discovery, Preclinical and Clinical
Antisense Oligonucleotides for Treatment of Cancer and Kidney Diseases
  • Frank Jaschinski, PhD. - Chief Scientific Officer, Secarna Pharmaceuticals
09:05 - 09:3530 mins
Oligonucleotide Chemistry, Manufacturing & Controls
Designing a Safe, Sustainable, and Efficient Drug Manufacturing Processes for Oligonucleotide Based Products
  • Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
09:05 - 09:3530 mins
Peptide Discovery to CMC
Targeting Membrane-bound Proteins Using Cell-based Biopanning of Cyclized CLIPS™ Peptides in Phage-displayed Libraries
  • Sheena Ong, PhD - Scientist, Biosynth
09:35 - 10:1540 mins
Networking Refreshment Break in Poster and Exhibit Hall
    10:15 - 10:4530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    RNA Therapies in Heart Failure - An Update
    • Janika Viereck, PhD - Head of R&D, Cardior Pharmaceuticals GmbH - a Novo Nordisk company
    10:15 - 10:4530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Plant Design and Manufacturing Challenges with Insights from Leqvio
    • Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
    10:15 - 10:4530 mins
    Peptide Discovery to CMC
    Development of HER-096 as a Disease Modifying Therapy for Parkinson’s Disease
    • Antti Vuolanto - Chief Executive Officer, Herantis Pharma plc
    10:45 - 11:1530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Clinical Update on Rugonersen
    • Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
    10:45 - 11:1530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    NMR Platform Methods for Content and Loop Structure of Oligonucleotides
    • Joan Malmstrøm, Ph.D. - Principal Scientist, CMC Analytical Support, Novo Nordisk A/S
    10:45 - 11:1530 mins
    Peptide Discovery to CMC
    Development of GUBamy, A Clinical Stage Long-acting Amylin Analogue Formulated at Neutral pH, Using StreaMLine - A ML-driven Peptide Drug Discovery Platform
    • Morten Lundh, Ph.D. - Director, Drug Discovery Innovation, Gubra A/S
    11:15 - 11:4530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Oligonucleotide IMT504, a Drug Candidate for Complex Regional Pain Syndrome. Preclinical and Phase-I Clinical Results
    • Alejandro Montaner - CEO, Immunalgia Therapeutics
    11:15 - 11:4530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Process Development & Manufacturing of Oligos
    • Sonja Merkas, Ph.D. - Founder, Livinovea
    • Yannick Fillon, PhD - Head of Oligonucleotide Process Chemistry, Biogen
    • Filippo Sladojevich, Ph.D. - Senior Principal Scientist, Hoffmann-La Roche
    • Ashish Garg, Ph.D. - Director, Drug Product Development, Eli Lilly and Company
    • Letizia Volpe, Ph.D. - Site MS&T Head Chemical Operations, Novartis
    11:15 - 11:4530 mins
    Peptide Discovery to CMC
    Targeted Innate Immune Stimulators as Therapeutics
    • Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
    11:45 - 11:505 mins
    Transition to Spotlight Presentations
      11:50 - 12:2030 mins
      Spotlight Presentation 1
      Oligo Manufacturing Innovations - From Synthesis through Concentration
      • Tom Krebstakies, PhD - Sales Manager - Europe & Asia, Asahi Kasei Bioprocess
      11:50 - 12:2030 mins
      Spotlight Presentation 2
      Streamline Your Nucleic Acid Therapeutics Development and Manufacturing
      • Charlotte LeKieffre, PhD - Biopharma Application Specialist, Agilent Technologies
      • Ralph Beneke - Product Specialist, Genomics, Agilent Technologies
      • Amanda Haas - Business Development Manager, Gene Editing Therapeutics, Agilent Technologies
      11:50 - 12:2030 mins
      Spotlight Presentation 3
      New Trends in Oligotherapeutics
      • Daniel Bachmann, PhD - Business Development Manager, Bachem AG
      12:20 - 13:2565 mins
      Networking Luncheon in Poster and Exhibit Hall
      • Kangming Chen, PhD - Head of mRNA & Plasmid Department, GenScript
      • Jiazhen Liang, PhD - Senior Scientist, GenScript
      13:25 - 13:5530 mins
      Spotlight Presentation 1
      The Latest Tools for the Characterization of mRNA and Oligonucleotide Biopharmaceuticals by CE and LC-MS
      • Stephen Lock, PhD - Senior Market Development Manager, SCIEX
      13:25 - 13:5530 mins
      Spotlight Presentation 2
      Advancing Oligonucleotide Process Development: Integrating First Principles for Process Characterization
      • Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
      13:25 - 13:5530 mins
      Spotlight Presentation 3
      New LC-MS Approaches for RNA Therapeutics to Ensure Process Consistency and Product Quality
      • Jonathan Fox - Consulting Scientist, Waters Corporation
      13:55 - 14:005 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Chairman's Remarks: Oligonucleotide Chemistry, Mechanism, SAR and Pre-Clinical
      • Troels Koch, PhD - Chief Technology Officer, MiNa Therapeutics
      13:55 - 14:005 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      Chairman's Remarks: Regulatory CMC Strategies and Lessons Learned from Various Oligonucleotide Programs
      • Daniel Waschke, Ph.D. - Technical Regulatory Manager, F. Hoffmann-La Roche Ltd.
      13:55 - 14:005 mins
      Peptide Discovery to CMC
      Chairman’s Remarks: Innovating Efficiencies in Peptide Chemistry, Manufacturing and Controls
      • Riccardo Bernasconi, Ph.D. - Director Business Development, Bachem
      14:00 - 14:3030 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications
      • Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
      14:00 - 14:3030 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      An Update on EMA Regulatory Guidelines for Oligonucleotides
      • René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
      14:00 - 14:3030 mins
      Peptide Discovery to CMC
      How to Develop a Close-to-commercial Manufacturing Process for Peptide Drug Substance
      • Gajan Santhakumar, Ph.D. - Associate Principal Scientist, Early Chemical Development, AstraZeneca
      14:30 - 15:0030 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Increasing ASO Stability with Chemical Modifications
      • Erich Koller, Ph.D. - Senior Principal Scientist, Roche Innovation Center Basel
      14:30 - 15:0030 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      How to Prepare for a Successful IND/IMPD When Developing Oligonucleotide Therapeutics
      • Hagen Cramer, PhD - Chief Technology Officer, QurAlis
      14:30 - 15:0030 mins
      Peptide Discovery to CMC
      Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand
      • Olivier Ludemann-Hombourger, PhD - Director, Global Innovation and Technology, PolyPeptide Group
      15:00 - 15:3030 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS
      • Beatriz Llamusi, PhD - Chief Executive Officer & Co Founder, Arthex Biotech S.L.
      15:00 - 15:3030 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      General Post-approval Observations and Trends in Oligo Programs from a Regulatory Perspective
      • Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
      15:00 - 15:3030 mins
      Peptide Discovery to CMC
      A Generalized PAT Approach for Fast Peptide Purification Process Development and Production Control in CMC Settings
      • Jörg Kittelmann, Ph.D. - Principal Scientist, CMC Downstream API Development, Novo Nordisk
      15:30 - 16:1545 mins
      Networking Refreshment Break in Poster and Exhibit Hall
      • Sophie Corbet - EMEA Bioprocessing Technical Service Manager, DuPont
      • Mathew Miller, PhD - Director, Life Science and RNA Technologies, Codexis
      16:15 - 16:4530 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      AIC468 - A Novel Antisense Oligonucleotide in Clinical Development for Treatment of BKV Infections
      • Eric van der Veer, PhD - Chief Innovation Officer, Hybridize Therapeutics
      • Tamara Pfaff - Head of Preclinical Development, AiCuris Anti-infective Cures AG
      16:15 - 16:4530 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      Regulatory CMC Insights on Post-approval Changes for a siRNA Oligonucleotide
      • Daniela Fischer, Ph.D. - Associate Director Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing
      16:15 - 16:4530 mins
      Peptide Discovery to CMC
      A Second-generation Process for the Manufacturing of Liraglutide
      • Alexander Kleinsmann, PhD - Director R&D, CMC Development, Bachem AG
      16:45 - 17:1530 mins
      Oligonucleotide Discovery, Preclinical and Clinical
      State of the Art siRNA - Delivery and Chemistry
      • Tomaz Einfalt, PhD - Principal Investigator II xRNA, Novartis Institutes for BioMedical Research
      16:45 - 17:1530 mins
      Oligonucleotide Chemistry, Manufacturing & Controls
      Enzymatic Ligation, Regulatory Challenges and Potential Platform Approaches
      • Sergey Tsukanov, Ph.D. - Senior Director Chemistry, Eli Lilly and Company
      16:45 - 17:1530 mins
      Peptide Discovery to CMC
      Optimizing Critical Peptide Impurity Management through Design of Experiments
      • Yi Yang, PhD - Lead Scientist, Ferring Pharmaceuticals A/S
      17:15 - 19:00105 mins
      Evening Networking Reception in Hamburg
        19:00 - 19:055 mins
        Close of Day Two
          Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm)
          NextMain Conference Day 3

          * 不測の事態により、事前の予告なしにプログラムが変更される場合があります。